PURPOSE: Tumor cell targeting is a promising strategy for enhancing the therapeutic potential of chemotherapy agents. Polyethylene glycol (PEG)-coated (sterically stabilized) liposomes show enhanced accumulation on the surface of tumors, but steric hindrance by PEGylation reduces the association of the liposome-bound ligand with its receptor. To increase folate receptor (FR) targeting, we optimized the concentration and PEG spacer length of folate-PEG-lipid in liposomes. EXPERIMENTAL DESIGN: Three types of folate-linked liposomal doxorubicin were designed and prepared by optimizing the concentration and PEG spacer length of folate-PEG-lipid in PEGylated or non-PEGylated liposomes and by masking folate-linked liposomes where the folate ligand is "masked" by adjacent PEG spacers. The liposome targeting efficacy was evaluated in vitro and in vivo. RESULTS: In human oral carcinoma KB cells, which overexpress FR, modification with sufficiently long PEG spacer and a high concentration of folate ligand to non-PEGylated liposomes increased the FR-mediated association and cytotoxicity more than with PEGylated and masked folate-linked liposomes. On the contrary, in mice bearing murine lung carcinoma M109, modification with the folate ligand in PEGylated and masked folate-linked liposomes showed significantly higher antitumor effect than with non-PEGylated liposomes irrespective of the length of time in the circulation after intravenous injection. CONCLUSIONS: The results of this study will be beneficial for the design and preparation of ligand-targeting carriers for cancer treatment.
PURPOSE: Tumor cell targeting is a promising strategy for enhancing the therapeutic potential of chemotherapy agents. Polyethylene glycol (PEG)-coated (sterically stabilized) liposomes show enhanced accumulation on the surface of tumors, but steric hindrance by PEGylation reduces the association of the liposome-bound ligand with its receptor. To increase folate receptor (FR) targeting, we optimized the concentration and PEG spacer length of folate-PEG-lipid in liposomes. EXPERIMENTAL DESIGN: Three types of folate-linked liposomal doxorubicin were designed and prepared by optimizing the concentration and PEG spacer length of folate-PEG-lipid in PEGylated or non-PEGylated liposomes and by masking folate-linked liposomes where the folate ligand is "masked" by adjacent PEG spacers. The liposome targeting efficacy was evaluated in vitro and in vivo. RESULTS: In humanoral carcinoma KB cells, which overexpress FR, modification with sufficiently long PEG spacer and a high concentration of folate ligand to non-PEGylated liposomes increased the FR-mediated association and cytotoxicity more than with PEGylated and masked folate-linked liposomes. On the contrary, in mice bearing murinelung carcinoma M109, modification with the folate ligand in PEGylated and masked folate-linked liposomes showed significantly higher antitumor effect than with non-PEGylated liposomes irrespective of the length of time in the circulation after intravenous injection. CONCLUSIONS: The results of this study will be beneficial for the design and preparation of ligand-targeting carriers for cancer treatment.
Authors: Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson Journal: Nat Rev Cancer Date: 2011-12-23 Impact factor: 60.716
Authors: Mohiuddin A Quadir; Stephen W Morton; Lawrence B Mensah; Kevin Shopsowitz; Jeroen Dobbelaar; Nicole Effenberger; Paula T Hammond Journal: Nanomedicine Date: 2017-03-02 Impact factor: 5.307
Authors: Suzanne M D'Addio; Steven Baldassano; Lei Shi; Lila Cheung; Douglas H Adamson; Matthew Bruzek; John E Anthony; Debra L Laskin; Patrick J Sinko; Robert K Prud'homme Journal: J Control Release Date: 2013-02-16 Impact factor: 9.776
Authors: David S H Chu; Joan G Schellinger; Michael J Bocek; Russell N Johnson; Suzie H Pun Journal: Biomaterials Date: 2013-09-13 Impact factor: 12.479